Pancreatic Cancer Therapeutics Market - Global Industry Analysis, Market Size, Opportunities and Forecast 2021 - 2028

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC2772

Pancreatic cancer is usually detected later and unintentional weight loss, persistent loss of appetite, etc. are some symptoms seen among patients. Surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy are smog treatments available for patients depending upon their condition.

Report coverage

Market Pancreatic Cancer Therapeutics Market
Analysis Period 2017 - 2028
Base Year 2020
Forecast Data 2021 - 2028
Segments Covered By Treatment Type, By End Use, and By Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Eli Lilly, Amgen Inc., Celgene Corp., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., Novartis AG, Threshold Pharmaceuticals Inc., and NewLink Genetics Corp.
Report Coverage
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Customization Scope 10 hrs of free customization and expert consultation


Market Dynamics

Pancreatic cancer is a growing concern among consumers across the globe. According to American Cancer Society, about 60,430 people (31,950 men and 28,480 women) are expected to be diagnosed with pancreatic cancer. The rate of new cases of pancreatic cancer was 13.2 per 100,000 men and women per year. Investment by major players for development of new solutions in order to enhance patient care is increasing. In addition, high investment by the government on development of healthcare infrastructure with the focus to enhance the patient experience and increase the care ratio these factors are expected to augment the growth of pancreatic cancer therapeutics market. In 2021, Lantern Pharma, a global biopharmaceutical company in collaboration with Fox Chase Cancer Center published the data from successful use of LP-184 for rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks. Enterprises are focused on new drug development with the increasing clinical trials, new drug approvals and introduction of new surgical solutions are impact the growth of target market.

In 2021, Novartis, a global drug development company received approval for Orphan Drug Designation (ODD) for NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer. This is expected to help company enhance its product portfolio.

In 2021, Prestige BioPharma Limited, a global drug manufacturing company announced that it has received Phase 1/2a clinical trial of its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.  This is expected to help company to expand its product portfolio in pancreatic cancer treatment and attract new customers.

In 2021, Algernon Pharmaceuticals Inc., a global drug re-purposing company initiated a new clinical research program for pancreatic cancer (PC) and NP-120 (Ifenprodil). Ifenprodil demonstrated a significant anti-tumour effect in a PC animal model which was reported in a paper published in the Dove Press Journal, Clinical Pharmacology: Advances and Applications.

Enterprises are focused on shifting their production unit to developing countries due to easy availability of raw material and low cost labor. In addition, availability of favorable business policies by the government and players inclination towards strategic partnership are factors expected to boost the market growth. Factors such as high cost associated to R&D activities, time consuming process and stringent government regulations related to product approval are expected to hamper the growth of global pancreatic cancer therapeutics market. In addition, lack of developed infrastructure in developing countries is expected to challenge the growth of target market. However, rise in investment by major players, increasing government spending on development of healthcare infrastructure and new introduction of new solutions are factors expected to create new opportunities for players operating in the pancreatic cancer therapeutics market over the forecast period. In addition, increasing PPP for R&D activities is expected to support the revenue transaction of the target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global pancreatic cancer therapeutics market due to rise in inpatient in hospitals related to cancer. Presence of well established infrastructure for R&D activities, availability of reimbursement policies and new drugs launches by major players are factors expected to augment the growth of pancreatic cancer therapeutics regional market. In addition, increasing acquisition activities by enterprises with the focus to enhance the business and increase the revenue share is expected to boost the growth of market.

Competitive Landscape      

The global pancreatic cancer therapeutics market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Pancreatic Cancer Therapeutics Market Segment Analysis, 2020

The global pancreatic cancer therapeutics market is segmented into treatment type and end use. The treatment type segment is bifurcated into surgery, chemotherapy, radiation therapy, and others. Among treatment type the surgery segment is expected to account for noticeable revenue share in the global market. The end use segment is divided into hospitals, clinics, research institutes, and others. The players operating in the global pancreatic cancer therapeutics market are F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Eli Lilly, Amgen Inc., Celgene Corp., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., Novartis AG, Threshold Pharmaceuticals Inc. and NewLink Genetics Corp.

Market Segmentation

Market By Treatment Type

Surgery
Chemotherapy
Radiation Therapy
Others

Market By End Use

Hospitals
Clinics
Research Institutes
Others

Market By Geography

North America
•    U.S.
•    Canada

Europe
•    U.K.
•    Germany
•    France
•    Spain
•    Rest of Europe

Asia-Pacific
•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Rest of Asia-Pacific

Latin America
•    Brazil 
•    Mexico
•    Rest of Latin America

Middle East & Africa
•    GCC
•    South Africa
•    Rest of Middle East & Africa


Frequently Asked Questions

Investment by major players for development of new solutions in order to enhance the patient care is increasing. In addition, high investment by the government on development of healthcare infrastructure with the focus to enhance the patient experience and increase the care ratio these factors are expected to augment the growth of pancreatic cancer therapeutics market.

In end use the hospital segment is growing at faster pace.

In the global market the Asia Pacific region is expected to grow faster.

Some of the players considered in the report scope are F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Eli Lilly, Amgen Inc., Celgene Corp., and Aduro BioTech Inc.

The North America is expected to account for major revenue share in the global market.

Factors such as high cost associated to R&D activities, time consuming process and stringent government regulations related to product approval are expected to hamper the growth of global pancreatic cancer therapeutics market.

Cart Summary


60